Genprex CEO to Interview Live on “The Big Biz Show”

Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that its Chairman and Chief Executive Officer, Rodney Varner, will be participating in a live interview with the “Big Biz Show,” an Emmy Award winning nationally syndicated TV and radio show, on Thursday, June 25.

The Big Biz Show covers current business events, internet-related issues and other hot topics in the business world. The Big Biz Show is seen and heard in over 100 million broadcast TV homes, 150 radio stations in the U.S. and in 175 countries. The Emmy Award winning show was named by TALKERS Magazine as one of the “Top 10 Most Influential Financial Shows.”

The Big Biz Show can be seen and heard every weeknight on YouTOO America Television Network at 8 p.m. ET, the following morning at 7 a.m. ET, and every weekday on BizTalk Radio at 2 p.m. ET. Additionally, the show can be accessed digitally by visiting BizTVClub.com, where you can watch the Big Biz Show every weeknight at 9 p.m. ET.

During the interview, Mr. Varner will discuss:

• How Genprex is bridging critical gaps in modern medicine by providing new treatment options to patients with cancer and diabetes
• The Company’s oncology program and its modern combinational treatment approach to fight cancer
• The Company’s U.S. FDA Fast Track Designation
• How its diabetes program could eliminate the need for insulin in diabetic patients

Following the interview, a video recording of Mr. Varner’s appearance on the Big Biz Show will be made available on Genprex’s website.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, Oncoprex, is being evaluated as a treatment for non-small cell lung cancer (NSCLC). Oncoprex has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for Oncoprex immunogene therapy for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.